UDP-Galactose Inhibitor Development Service

UDP-Galactose Inhibitor Development Service

UDP-Galactose Inhibitor Development Service at CD BioGlyco

UDP-Galactose is an important biosynthetic intermediate involved in a variety of biological processes, including glycoprotein synthesis, immune response, and cell signaling. The growth and metastasis of some tumor cells depend on the modification and expression of glycoproteins, and the development of inhibitors targeting this process to inhibit the production of UDP-galactose can interfere with the synthesis of glycoproteins in tumor cells, thereby inhibiting their growth and metastasis. Therefore, the research and development of UDP-galactose inhibitors is a hot research topic. CD BioGlyco has been engaged in Glycosylation Inhibitor Development research for many years. We have experienced researchers, providing you with assured UDP-galactose inhibitor development services.

The process of our UDP-galactose inhibitor development service involves the steps of target identification, compound screening, activity validation, optimization, and drug property assessment. First, we research to determine the biological functions of UDP-galactose in organisms and its role in diseases. The compounds are then screened by high-throughput screening techniques, which in turn validate the inhibitory activity of the compounds against UDP-galactose. Based on this, structure optimization is performed and drug properties such as toxicity and metabolic properties are evaluated.

General process of UDP-galactose inhibitor development. (CD BioGlyco)Fig.1 General process of UDP-galactose inhibitor development. (CD BioGlyco)

The types of UDP-galactose inhibitor development services we offer include but are not limited to:

  • Competitive inhibitor development
    We design and synthesize competitive inhibitors of UDP-galactose that have similar binding sites to UDP-galactose and bind competitively to the same receptors or enzymes as UDP-galactose, thereby inhibiting the binding of UDP-galactose and reducing its biological activity.
  • Non-competitive inhibitor development
    We design and synthesize inhibitors that bind to other sites of the receptor or enzyme to which UDP-galactose is intended to bind, resulting in a conformational change in the receptor or enzyme that affects the binding and activity of UDP-galactose.
  • Trans-inhibitor development
    We inhibit the production of UDP-galactose by synthesizing inhibitors or accelerate the degradation of UDP-galactose, thereby reducing its intracellular level.
  • Other inhibitor development


  • UDP-Galactose inhibitors can be used as targets in drug discovery for exploring new drugs for the treatment of disorders related to sugar chain synthesis.
  • By interfering with the utilization of UDP-galactose by viruses, the replication and spread of viruses can be prevented, providing new ideas for antiviral drug development.
  • In biotechnology, UDP-galactose inhibitors can be used to modulate glycoprotein synthesis and play an essential role in the production of recombinant proteins or glycoprotein drugs.

Frequently Asked Questions

  • Q1: What is the role of UDP-galactose in the cells?
    UDP-Galactose is primarily associated with glycan chain synthesis and modification in cells. Specifically, in the glycan chain synthesis pathway, UDP-galactose acts as a glycosyl donor that interacts with specific enzymes to transfer galactose units to different acceptor molecules, resulting in the formation of various complex glycan chain structures.
  • Q2: What diseases are associated with UDP-galactose?
    Diseases associated with UDP-galactose are usually rare inherited metabolic disorders such as galacturonate synthase deficiency, which causes galactose to not be metabolized properly in the body, which in turn causes digestive problems.

Pathways of galactose metabolism. (Schulz, et al., 2005)Fig. 2 Pathways of galactose metabolism. (Schulz, et al., 2005)

At CD BioGlyco, our research team of seasoned researchers specializing in chemistry and biology is ready to support clients in their quest to develop effective UDP-galactose inhibitors. If you require our services, please do not hesitate to contact us.


  1. Schulz, J.M.; et al. Mediators of galactose sensitivity in UDP-galactose 4'-epimerase-impaired mammalian cells. Journal of Biological Chemistry. 2005, 280(14): 13493-13502.
This service is for Research Use Only, not intended for any clinical use.

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.